226 related articles for article (PubMed ID: 27425647)
1. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
3. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
4. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
5. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
6. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
7. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
9. Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase).
Sbodio JI; Lodish HF; Chi NW
Biochem J; 2002 Feb; 361(Pt 3):451-9. PubMed ID: 11802774
[TBL] [Abstract][Full Text] [Related]
10. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner.
Sbodio JI; Chi NW
J Biol Chem; 2002 Aug; 277(35):31887-92. PubMed ID: 12080061
[TBL] [Abstract][Full Text] [Related]
12. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase: a promising therapeutic target with pleiotropic action.
Sagathia V; Patel C; Beladiya J; Patel S; Sheth D; Shah G
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3363-3374. PubMed ID: 37338576
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres.
Smith S; Giriat I; Schmitt A; de Lange T
Science; 1998 Nov; 282(5393):1484-7. PubMed ID: 9822378
[TBL] [Abstract][Full Text] [Related]
15. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1.
Yeh TY; Sbodio JI; Nguyen MT; Meyer TN; Lee RM; Chi NW
Mol Cell Biochem; 2005 Aug; 276(1-2):183-92. PubMed ID: 16132700
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length.
Rippmann JF; Damm K; Schnapp A
J Mol Biol; 2002 Oct; 323(2):217-24. PubMed ID: 12381316
[TBL] [Abstract][Full Text] [Related]
18. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
[TBL] [Abstract][Full Text] [Related]
20. NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis.
Chang W; Dynek JN; Smith S
Biochem J; 2005 Oct; 391(Pt 2):177-84. PubMed ID: 16076287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
